Flucelvax

Quick links to important sections

Flucelvax

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flucelvax

Property Description
Active Ingredients Influenza virus hemagglutinin and neuraminidase antigens
Form Suspension for injection (Intramuscular)
Pharmacological Class Vaccine, Active Immunizing Agent
Common Use Prophylaxis against seasonal influenza (persons 6 months and older)
Origin Cell-culture derived (non-egg-based)

What Type of Prophylactic Vaccine is Flucelvax?

Flucelvax is classified as a prescription biological product and an active immunizing agent, belonging to the vaccine pharmacological class. Its general purpose is to provide prophylaxis (prevention) against the seasonal influenza illness for individuals six months of age and older. The drug entity is an inactivated influenza vaccine, meaning the preparation contains non-live viral components, and is supplied as a suspension for injection administered via intramuscular injection. This method of active immunization is recognized as a primary public health measure against seasonal influenza. This confirms that the medicine's role is to stimulate the immune system rather than treating an existing infection. It is typically a quadrivalent formulation, designed to stimulate an immune response against four specific virus strains—two Influenza A subtypes and two Influenza B types—which are annually selected to match expected circulating threats.


Composition and Origin: The Cell-Culture Difference

The active components of Flucelvax are the specific Influenza virus hemagglutinin and neuraminidase surface antigens derived from the four targeted virus strains. A key differentiating factor of its origin/type is that Flucelvax is a cell-culture based vaccine (ccIIV). This production method involves propagating the viral components in cultured mammalian cells, such as Madin Darby Canine Kidney (MDCK) cells, rather than using fertilized chicken eggs, the process utilized for many conventional egg-based influenza vaccines. Retrospective studies have suggested that the cell-culture technology yields candidate vaccine viruses that are more antigenically similar to the original wild-type viruses, particularly for challenging strains like A(H3N2). This supports the concept that the cell-based platform may result in a potentially better match between the vaccine components and the circulating virus strains. The final preparation consists of these purified antigens suspended in a buffered aqueous saline solution (phosphate buffered saline).

What side effects are possible with Flucelvax?

Possible Side Effects and Safety Information

Adverse reactions associated with Flucelvax are officially documented and classified by frequency and affected physiological system. The safety profile is characterized primarily by localized reactions at the injection site and common systemic events, which typically occur in the acute post-vaccination period, generally within three days of administration.


Frequency-Classified Adverse Reactions

The majority of documented reactions fall into the Very Common (ge 1/10) and Common (ge 1/100 to < 1/10) categories. Very Common reactions include injection site pain/tenderness, erythema, induration, headache, fatigue, and myalgia. Common reactions include injection site swelling, fever, malaise, arthralgia, and chills. Less frequent effects are classified as Uncommon (e.g., dizziness, paresthesia, vomiting) or Rare (allergic reactions).


System-Organ-Class Groupings and Serious Risks

Reactions are grouped into System-Organ Classes (SOCs), such as General Disorders and Administration Site Conditions (fever, pain), Nervous System Disorders (headache), and Musculoskeletal Disorders (muscle and joint pain). Anaphylaxis (a severe allergic reaction) is documented in post-marketing surveillance as a rare, serious risk. Regulatory bodies also require caution regarding patients with a history of Guillain-Barré Syndrome (GBS) within six weeks of prior influenza vaccination.


Population-Specific Safety and Restrictions

Official labels detail separate safety considerations for specific groups. Pediatric patients (6 months to less than 9 years) may exhibit different frequency rates for systemic reactions like irritability and sleepiness compared to Older Adults (ge 65 years). Use is contraindicated in individuals with a history of a severe allergic reaction to any component of the vaccine or a previous dose.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory prescribing information for Flucelvax (influenza vaccine, surface antigen, inactivated) provides a highly constrained profile concerning over-administration. This section outlines the information explicitly documented by government health authorities regarding overdose.

Official Overdose Data Status

Feature Official Regulatory Statement
Documented Overdose Manifestations None documented. Regulatory labels explicitly state that no specific data is available on the effects or management of a true overdose of the vaccine.
Overdose Treatment No specific antidote or procedural steps for overdose management are listed in the official documentation. Treatment would be supportive, as clinically indicated.

Emergency Help-Seeking Requirements

Since there are no documented overdose symptoms, the only official instruction regarding urgent help-seeking relates to the general mandatory preparedness for all injectable vaccines.

  • Immediate medical treatment and supervision must be available to manage any acute and severe reactions, such as anaphylaxis, which are rare but potential events following the administration of the vaccine.
  • Urgent medical attention is required if signs of a severe allergic reaction (e.g., difficulty breathing, swelling of the face or throat, rapid pulse) are observed following vaccination.

This regulatory focus on the absence of overdose data and the mandate for immediate management of anaphylaxis defines the entirety of the official overdose and emergency-action profile for Flucelvax.

Therapeutic Uses of Flucelvax

What Flucelvax Treats: Main Uses and Benefits

Flucelvax is relevant for the prevention of seasonal influenza caused by the specific Influenza A and B virus strains contained within the annual formulation. Its therapeutic application is generally relevant across individuals six months of age and older.

The therapeutic use may assist with reducing the potential for severe influenza outcomes, a domain where the medication is commonly used to help reduce the potential for clinical scenarios that lead to flu-related hospitalization or require intensive care. This protective approach helps address symptom clusters related to systemic imbalance and acute episodes. The vaccine supports the patient during symptomatic episodes by easing the overall symptom load related to conditions where symptoms may intensify temporarily.

Its use is commonly associated with the prevention of seasonal flu illness and reducing the potential for serious consequences in patients, especially children and older adults (ge 65 years). The vaccine contributes to easing the overall symptom load during periods of heightened discomfort and provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Supports Prevention of Systemic Symptoms (Flucelvax is applied in addressing conditions that may intensify temporarily, and is relevant for managing symptoms related to systemic imbalance associated with acute influenza illness.)

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Flucelvax — Official Regulatory Information

Category Official Regulatory Statement
Populations for whom use is allowed Persons 6 months of age and older are approved for use [FDA Prescribing Information; EMA SmPC].
Populations for whom use is contraindicated Individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any vaccine component or previous influenza vaccine [FDA Prescribing Information; EMA SmPC].
Age-related eligibility rules Minimum Age: Use is not established and not approved for children under 6 months of age [EMA SmPC].
Pregnancy and lactation eligibility status Pregnancy: The vaccine can be given in any stage of pregnancy [EMA SmPC]. Lactation: The vaccine may be given during lactation [EMA SmPC].
Eligibility-related restrictions Altered Immunocompetence: Immunocompromised individuals may have a reduced immune response, noted as a limitation of vaccine effectiveness [FDA Prescribing Information].
Conditional Use Vaccination should be postponed in patients with an acute severe febrile illness until the fever is resolved [Health Canada Product Monograph].

Connection to the overall eligibility profile

Regulatory documents define eligibility primarily by a mandatory minimum age threshold of 6 months and an absolute exclusion for individuals with a history of severe allergic reactions. For other populations, such as pregnant or breastfeeding women, use is explicitly permitted. Individuals with specific pre-existing conditions, such as a history of Guillain-Barré Syndrome (GBS), require special consideration due to safety warnings listed in the official labeling.

What should I know about interactions with other medicines?

Flucelvax Interactions with other medicines and products

The official interaction profile for Flucelvax is primarily documented as pharmacodynamic interaction patterns that affect the immune response or require procedural restrictions for administration.

There are no explicitly documented pharmacokinetic (CYP- or transporter-mediated) interactions, or official prohibitions, with oral non-vaccine medicines, food, alcohol, or supplements in regulatory labels.


Documented Pharmacodynamic Interactions

Classification Official Regulatory Statement
Immunosuppressive Therapy Administration to individuals receiving immunosuppressive therapies (e.g., corticosteroids, chemotherapy) may result in a reduced immune response (Altered Immunocompetence), as stated in regulatory prescribing information.
Co-administration with Other Vaccines Flucelvax can be given at the same time as other vaccines (pharmacodynamic compatibility).

Interaction-Related Constraints

Constraint Type Regulatory Requirement
Procedural Restriction When co-administered with other injectable vaccines, they must be administered at separate injection sites and preferably on different limbs, to avoid localized interference.
Formulation Restriction The vaccine must not be mixed with other vaccines in the same syringe.
Population Note Immunocompromised individuals are specifically noted as potentially having a reduced immune response to the vaccine.

These patterns define the official interaction structure, which is focused on vaccine immunogenicity rather than typical drug metabolism.

Mechanism of Action

Flucelvax is an inactivated, subunit influenza vaccine that operates by engaging the adaptive immune system to establish antigen-specific immunological memory. The mechanism begins with the Antigenic Presentation and Recognition domain, where purified viral surface antigens, specifically haemagglutinin and neuraminidase, are administered. These components are captured by antigen-presenting cells, initiating the immune cascade through the recognition of viral epitopes. The primary effect is the activation of the Humoral Immunity Pathway. This involves the stimulation of naive B lymphocytes to proliferate and differentiate into plasma cells and long-lived memory B cells. Plasma cells mediate the de novo production of high-affinity, virus-neutralizing antibodies (IgG) targeting the vaccine antigens. The Establishment of Immunological Memory cluster focuses on the generation and maturation of these memory B and T cell populations. These cells drive a rapid secondary antibody-mediated response upon future exposure to the corresponding viral antigen, resulting in the neutralization of the antigen and prevention of viral attachment to host cells.

Dosage and Administration Information

Official Administration Instructions for Flucelvax

Flucelvax (influenza virus vaccine) is administered as an intramuscular (IM) injection for active immunization against influenza disease. It is approved for use in persons 6 months of age and older.


Dosing Schedule and Age Groups

The standard dose for all age groups is 0.5 mL per injection.

Age Group Dose Volume Schedule
9 years and older 0.5 mL One single dose per influenza season.
6 months through 8 years 0.5 mL One or two doses per influenza season. If two doses are required (based on prior vaccination history), they must be administered at least 4 weeks apart.

Procedural Steps

  1. Preparation: Before use, the syringe should be shaken vigorously (or the multi-dose vial shaken each time a dose is withdrawn).
  2. Inspection: Visually inspect the slightly opalescent suspension for particulate matter or discoloration. Do not administer the vaccine if either condition is present.
  3. Injection Site: The vaccine is administered into the deltoid muscle of the upper arm. For younger children (e.g., 6 months through 3 years) with insufficient deltoid muscle mass, the injection may be given in the anterolateral aspect of the thigh muscle.

Flucelvax is intended for annual use to protect against circulating influenza strains. It is for intramuscular administration only and must not be administered intravenously, intradermally, or subcutaneously.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flucelvax

This section provides an overview of the types of clinical studies and real-world evidence that informed the regulatory review of Flucelvax, including the designs, populations, and outcomes examined by researchers.


Evidence for Prevention of Seasonal Influenza Illness

The primary research for Flucelvax included Randomized Controlled Trials (RCTs). These are study designs where people are randomly assigned to receive either the vaccine being studied or a comparison product. Researchers used these trials to research examined the occurrence of laboratory-confirmed, medically-attended influenza illness. This means the studies were used to monitor if a person developed flu-like symptoms that required a doctor's visit and then tested positive for the flu strains contained in the vaccine.

In these trials, a key outcome that was studied for was immunogenicity, which describes the degree of antibody response generated following receipt of the vaccine. Studies report how antibody levels evolved in the observed populations during the short-term period following vaccination.

Long-term outcomes are not fully established regarding the durability of the immune response beyond the typical short follow-up periods of the immunogenicity studies. Also, the results of efficacy studies are inherently season-specific, meaning they reflect the circulating virus strains and match only during the period when the study was conducted.


Comparative Studies and Real-World Evidence (RWE)

Research has explored how studies evaluated the cell-culture based platform against other licensed seasonal influenza vaccines. This research primarily relies on Real-World Evidence (RWE), which uses observational study designs to monitor outcomes in routine clinical practice. These studies explored the differences in measured outcomes when comparing Flucelvax to standard egg-based influenza vaccines.

Observational studies data show patterns related to the occurrence of severe outcomes and outcomes linked to inflammatory or irritative states, such as influenza-related hospitalization or emergency room visits. Findings from these real-world comparisons have varied, which is expected since the research is derived from settings with varying symptom burdens and patient health statuses.

Subgroup findings are uncertain when trying to draw conclusions about specific high-risk patient populations compared to other enhanced preventative measures. Research is ongoing to continue building the evidence landscape.

Key Studies & References

  1. Effectiveness of Cell-Based Quadrivalent Seasonal Influenza Vaccine: A Systematic Review and Meta-Analysis
  2. FLUCELVAX quadrivalent (ccIIV4) a phase III randomized controlled trial: immunogenicity & safety results in young children (6 through 47 months of age)

Frequently Asked Questions (FAQ)

Common questions about Flucelvax (FAQ)


Q: Why is Flucelvax grown in cells and not eggs?

Flucelvax is manufactured using a cell-culture process instead of the chicken eggs used for some other flu vaccines. This process is used because it may yield a virus strain that is a closer antigenic match to the strains circulating in the wild. Regulatory reviews note that this method aims to prevent potential changes to the virus that can sometimes occur when it is grown in eggs.


Q: What specific strains of the flu does Flucelvax protect against?

According to official product information, Flucelvax is a quadrivalent vaccine, meaning it is designed to protect against four specific influenza virus strains. These strains—two type A and two type B—are selected annually by global health bodies to target the viruses expected to be the most common during the upcoming flu season.


Q: Does Flucelvax contain mercury or thimerosal?

Official product information confirms that Flucelvax Quadrivalent is supplied in single-dose presentations. These presentations do not contain thimerosal, which is a mercury-containing preservative found in some multi-dose vials of other vaccines.


Q: How quickly after getting Flucelvax does protection start?

Regulatory information indicates that it generally takes about two weeks after vaccination for the body to develop the necessary antibodies to protect against the flu virus.


Q: How long does the protection from Flucelvax last?

Protection from any influenza vaccine is considered transient, meaning it does not last indefinitely. Official information notes that immune protection may decline over time. This decline is one of the factors considered by public health bodies when suggesting annual vaccination.


Q: Are there any preservatives in Flucelvax?

Flucelvax is typically supplied in single-dose vials and pre-filled syringes. These single-dose presentations are preservative-free, meaning they do not contain thimerosal.


Q: Is Flucelvax considered safe for people with egg allergies?

Yes. Because Flucelvax is a cell-culture based vaccine, it does not contain egg protein. Regulatory guidance indicates that individuals with an egg allergy may receive any influenza vaccine appropriate for their age, including this cell-culture based product.


Q: Does Flucelvax contain any antibiotics?

According to manufacturing summaries, the Flucelvax production process is designed to be free of eggs and antibiotics.


Q: Is there a different way Flucelvax works compared to traditional flu shots?

The core mechanism of action—stimulating the immune system to produce protective antibodies—is similar to that of traditional inactivated flu shots. However, the key difference is in its production method: Flucelvax is grown in cell cultures, not chicken eggs.


Q: Can people with chronic conditions like asthma get Flucelvax?

Official health guidance indicates that influenza vaccination is typically recommended for all eligible individuals ge 6 months of age. This includes adults and children with chronic health conditions, such as asthma, as regulatory bodies often advise vaccination for these groups.


Q: Is Flucelvax recommended for healthy adults?

The vaccine is approved for people 6 months of age and older. Regulatory bodies and public health organizations generally advise annual influenza vaccination for everyone in the approved age group, which includes healthy adults.


Q: What should I tell my healthcare provider about before getting Flucelvax?

Official warnings and precautions list certain conditions that should be discussed with a healthcare provider. These include any history of severe allergic reaction to a vaccine component, a history of Guillain-Barré Syndrome (GBS) after a prior flu shot, or the presence of an acute severe febrile illness (fever). You should also inform them of any history of bleeding disorders.


Q: Does Flucelvax contain latex?

According to public health guidance on vaccine packaging, the components used for the flu vaccine, including Flucelvax, are not typically packaged in materials that contain latex.


Q: Why do some people prefer Flucelvax over other flu shots?

The primary reason for interest is its cell-culture based origin, which makes it egg-free. Some people may also prefer it due to research suggesting that the cell-culture method can result in a virus that is an appropriate antigenic match to circulating strains.


Q: Is there evidence that Flucelvax is effective for the current flu season?

Regulatory processes confirm that the vaccine's composition is updated annually based on recommendations from the WHO. This process is designed to target the specific four flu strains that are expected to be circulating during the current season.


Q: Does Flucelvax have a specific lot number or dating system I should know about?

Yes. To maintain proper tracking and safety surveillance, regulatory bodies require that the name and batch number (or lot number) of the administered vaccine dose be clearly recorded for documentation and traceability purposes.


Q: What is the difference between Flucelvax and the high-dose flu shot?

These are different products intended for different populations. The high-dose flu shot is specifically approved for people 65 years of age and older and contains four times the antigen found in a standard-dose product like Flucelvax.


Q: What happens if I miss the 'ideal' time to get Flucelvax?

Official public health guidance states that vaccination can still be considered and administered later in the season. This is permitted even after the typically recommended time frame, as long as flu viruses are still actively circulating in the community.


Q: Why is annual vaccination with Flucelvax needed?

Annual vaccination is required for two main reasons. First, the immune protection provided by the vaccine naturally declines over time. Second, the specific influenza virus strains circulating change every year, requiring the vaccine to be updated annually to match the expected threats.


Q: What is the ingredient list for Flucelvax?

The active ingredients are the influenza virus surface antigens. The inactive ingredients, known as excipients, include buffering salts (like sodium chloride and potassium chloride) to maintain the solution's stability, and water for injection. The product may also contain trace residues from the manufacturing process, such as beta-propiolactone.


Q: Does Flucelvax have different types of formulations (e.g., one for older adults)?

No. Flucelvax is administered as a standard single formulation with a 0.5 mL dose approved for all eligible age groups, starting at 6 months of age. There are no different formulations of Flucelvax specifically for older adults.


Q: What is the difference between an inactivated vaccine and a recombinant one?

Flucelvax is classified as an inactivated vaccine, which means it contains non-live, purified viral components. A recombinant vaccine is a different type of product that is manufactured by producing a specific flu protein in a laboratory and then purifying it, without needing to grow the whole virus.


Q: Has Flucelvax been tested in pregnant individuals?

Clinical studies have examined the use of Flucelvax in pregnant individuals. Based on the safety data collected, official documents state there was no apparent evidence of adverse fetal, newborn, or pregnancy outcomes that could be attributed to the vaccine during any stage of pregnancy.


Q: What are the official warnings listed for Flucelvax?

Official warnings and precautions are noted in the product information. These include the potential for a reduced immune response in immunocompromised individuals and caution regarding patients with a history of Guillain-Barré Syndrome (GBS). The risk of syncope (fainting) and the need for immediate treatment for anaphylactic reactions are also noted.


Q: What should I do if I notice an allergic reaction after receiving Flucelvax?

While product information mandates that appropriate medical treatment be immediately available when the vaccine is given, any sign of a severe allergic reaction after you leave the facility suggests the need for immediate medical assistance. Symptoms that should be monitored include difficulty breathing, swelling of the face or throat, or dizziness.


Q: Can Flucelvax be stored at home for later use?

Flucelvax must be stored under strict temperature controls, specifically in a refrigerator between 2 C and 8 C (36 F and 46 F), and must not be frozen. These storage requirements dictate that the product must be managed by healthcare providers or pharmacies.


Q: How is the effectiveness of Flucelvax measured each year?

Effectiveness is measured annually through clinical studies, including randomized trials. These studies evaluate two primary factors: the occurrence of laboratory-confirmed influenza illness in vaccinated groups, and the level of antibody response (known as immunogenicity) generated by the vaccine.


Q: Does Flucelvax contain formaldehyde?

Formaldehyde is sometimes used as an inactivating agent during the manufacture of flu vaccines. It is removed during the production process, and any trace amount of residual formaldehyde that may remain in the final product is at a level considered safe by regulatory bodies.


Q: What are the ingredients that are not part of the active drug in Flucelvax?

The inactive ingredients, known as excipients, include buffering salts (such as sodium chloride and potassium chloride) used to balance the solution, as well as water for injection. Official documentation notes that the product may also contain trace amounts of certain manufacturing components.


Q: Why are people who received Flucelvax asked to report side effects?

The reporting of any adverse reaction is part of a critical regulatory process known as post-marketing surveillance. This system allows regulatory bodies to continuously monitor the long-term safety profile of the medicine after it has been made available to the public.

How should Flucelvax be stored and disposed of?

Storage Requirements

Flucelvax is a temperature-sensitive vaccine that must be stored under controlled conditions to maintain its labeled potency.

Detail Official Regulatory Requirement
Temperature Store in a refrigerator between 2 C and 8 C (36 F and 46 F).
Prohibited Environment Do Not Freeze. Any product that has been frozen must be discarded.
Protection Protect from light and store in the original package/carton.
Child Safety Keep out of the sight and reach of young children.

Disposal Instructions

Disposal of Flucelvax and related waste must follow proper pharmaceutical protocols.

  • Unused Product: Disposal of unused or expired vaccine must be conducted in compliance with federal, state, and local regulations.
  • Sharps: Used needles and syringes must be placed in a designated rigid sharps container.
  • Environmental Rule: The unused product should not be flushed down sewers or placed in household trash, as specialized pharmaceutical waste handling is required.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Flucelvax found in:

A-Z Index: